Literature DB >> 25188020

Implication of HLA-C and KIR alleles in human papillomavirus infection and associated cervical lesions.

Roberta Rizzo1, Valentina Gentili, Antonella Rotola, Daria Bortolotti, Enzo Cassai, Dario Di Luca.   

Abstract

Human papillomavirus (HPV) regulation of host immune response leads to cervical lesions. In particular, natural killer (NK) cells are crucial for HPV control. Since specific HLA-I/KIR interactions modify NK cell activation, we analyzed HLA-C and KIR alleles in HPV infection and lesion development in 150 controls, 33 condyloma acuminatum, and 111 invasive cervical cancer (ICC) patients. We showed an increase in HLA-C1/KIR2DL2 and HLA-C1/KIR2DL3 pairs in HPV high-risk infected patients (OR 3.05, 3.24) with ICC (OR 1.33, 3.68). These data suggest HLA-C and KIR typing as risk marker for HPV infection and lesion evolution.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25188020     DOI: 10.1089/vim.2014.0017

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  8 in total

1.  HLA and KIR Associations of Cervical Neoplasia.

Authors:  Xiao Bao; Aimee L Hanson; Margaret M Madeleine; Sophia S Wang; Stephen M Schwartz; Felicity Newell; Ulrika Pettersson-Kymmer; Kari Hemminki; Sven Tiews; Winfried Steinberg; Janet S Rader; Felipe Castro; Mahboobeh Safaeian; Eduardo L Franco; François Coutlée; Claes Ohlsson; Adrian Cortes; Mhairi Marshall; Pamela Mukhopadhyay; Katie Cremin; Lisa G Johnson; Suzanne M Garland; Sepehr N Tabrizi; Nicolas Wentzensen; Freddy Sitas; Cornelia Trimble; Julian Little; Maggie Cruickshank; Ian H Frazer; Allan Hildesheim; Matthew A Brown; Emma L Duncan; Ying Pu Sun; Paul J Leo
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

2.  Inhibitory KIR2DL2 receptor and HHV-8 in classic or endemic Kaposi sarcoma.

Authors:  Daria Bortolotti; Monica Corazza; Antonella Rotola; Dario Bencivelli; Giovanna Schiuma; Elisabetta Danese; Sabrina Rizzo; Silvia Beltrami; Roberta Rizzo; Alessandro Borghi
Journal:  Clin Exp Med       Date:  2022-02-15       Impact factor: 3.984

Review 3.  Natural killer cell education in human health and disease.

Authors:  Jeanette E Boudreau; Katharine C Hsu
Journal:  Curr Opin Immunol       Date:  2018-02-03       Impact factor: 7.486

Review 4.  Cervical Carcinogenesis and Immune Response Gene Polymorphisms: A Review.

Authors:  Akash M Mehta; Merel Mooij; Ivan Branković; Sander Ouburg; Servaas A Morré; Ekaterina S Jordanova
Journal:  J Immunol Res       Date:  2017-02-09       Impact factor: 4.818

Review 5.  Activities of stromal and immune cells in HPV-related cancers.

Authors:  Marconi Rego Barros; Cristiane Moutinho Lagos de Melo; Maria Luiza Carneiro Moura Gonçalves Rego Barros; Rita de Cássia Pereira de Lima; Antonio Carlos de Freitas; Aldo Venuti
Journal:  J Exp Clin Cancer Res       Date:  2018-07-05

6.  Diagnostic and prognostic biomarkers of Human Leukocyte Antigen complex for hepatitis B virus-related hepatocellular carcinoma.

Authors:  Xiang-Kun Wang; Xi-Wen Liao; Cheng-Kun Yang; Ting-Dong Yu; Zheng-Qian Liu; Yi-Zhen Gong; Ke-Tuan Huang; Xian-Min Zeng; Chuang-Ye Han; Guang-Zhi Zhu; Wei Qin; Tao Peng
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

7.  Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells via Vav1-Dependent NF-κB Disinhibition.

Authors:  Hongli Liu; Sihui Zhou; Jing Liu; Fuliang Chen; Yuan Zhang; Mengjun Liu; Shengping Min; Hongtao Wang; Xiaojing Wang; Nan Wu
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

8.  Association between HLA-C alleles and COVID-19 severity in a pilot study with a Spanish Mediterranean Caucasian cohort.

Authors:  Lorena Vigón; Miguel Galán; Montserrat Torres; Antonio J Martín-Galiano; Sara Rodríguez-Mora; Elena Mateos; Magdalena Corona; Rosa Malo; Cristina Navarro; María Aránzazu Murciano-Antón; Valentín García-Gutiérrez; Vicente Planelles; Jorge Martínez-Laso; María Rosa López-Huertas; Mayte Coiras
Journal:  PLoS One       Date:  2022-08-12       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.